Switch to
View more

Aurobindo Pharma Ltd

AUROPHARMA
Health CarePharmaceuticals
MidcapWith a market cap of ₹31,253 cr, stock is ranked 148
Low RiskStock is 1.92x as volatile as Nifty
533.404.15 (+0.78%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
MidcapWith a market cap of ₹31,253 cr, stock is ranked 148
Low RiskStock is 1.92x as volatile as Nifty

Key Metrics

PE RatioPE Ratio
11.80
PB RatioPB Ratio
1.43
Dividend YieldDiv. Yield
0.84%
Sector PESector PE
32.97
Sector PBSector PB
4.55
Sector Div YldSctr Div Yld
0.97%

Forecast & RatingsDetailed Forecast 

83%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Aurobindo Pharma Limited is a pharmaceutical company. The Company is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs).

Brands

Aurobindo Pharma

Pharmaceutical company

Investor PresentationView older 

May 30, 2022

PDF
View Older Presentations

Brands

Aurobindo Pharma

Pharmaceutical company

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

See Plans

Financial TrendFinancial statements 

201920202021202219.7223.2928.4023.782.362.855.332.65
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

General updates 
Announced OnJul 4, 2022

Aurobindo Pharma Limited has informed the Exchange about Further to our intimation dated March 28, 2022, wherein we informed about the approval of the Board of Directors of the Company for the acquisition of business and certain assets of Veritaz Healthcare Limited, we hereby inform you that the said transaction has been completed today i.e July 4, 2022. | Download

Aurobindo Pharma Limited has informed the Exchange about Further to our intimation dated March 28, 2022, wherein we informed about the approval of the Board of Directors of the Company for the acquisition of business and certain assets of Veritaz Healthcare Limited, we hereby inform you that the said transaction has been completed today i.e July 4, 2022. | Download

Closure of trading window 
Announced OnJun 28, 2022

This is to inform that as per the Company¬タルs Internal Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons, the Trading Window for dealing in the securities of the Company would remain closed for all designated persons including promoters, directors, key managerial personnel, employees, connected persons and their immediate relatives with effect from July 1, 2022 till 48 hours after the declaration of the Unaudited Financial Results of the Company for the first quarter ending on June 30, 2022. The date of Board Meeting for declaration of the financial results of the Company for the first quarter ending on June 30, 2022 will be intimated in due course. | Download

This is to inform that as per the Company¬タルs Internal Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons, the Trading Window for dealing in the securities of the Company would remain closed for all designated persons including promoters, directors, key managerial personnel, employees, connected persons and their immediate relatives with effect from July 1, 2022 till 48 hours after the declaration of the Unaudited Financial Results of the Company for the first quarter ending on June 30, 2022. The date of Board Meeting for declaration of the financial results of the Company for the first quarter ending on June 30, 2022 will be intimated in due course. | Download

Cash Dividend 
Ex. DateJun 6, 2022

Interim 4 • Div/Share: ₹ 4.5

See all events